{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"ADAPT-C","nct_id":"NCT04585490","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=adapt-c-nct04585490. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects with detectable ctDNA will receive 4 cycles of platinum doublet chemotherapy \\[carboplatin/pemetrexed\\], tremelimumab (75 mg IV every 21 days) and durvalumab (1500 mg IV every 21 days), except subjects with squamous cell carcinoma histology will receive carboplatin/paclitaxel. Subjects will be evaluated with PET/CT and/or computed tomography (CT) thorax every 12 weeks. Following ctDNA evaluation, in the absence of progression or toxicity, subject will continue with durvalumab to complete 1 year of treatment as standard of care.","label":"Cohort 1 minimal residual disease positive (MRD+)","type":"EXPERIMENTAL"},{"description":"Subjects with undetectable ctDNA at study enrollment will receive standard of care durvalumab (10 mg/kg every 2 weeks, or equivalent, for 1 year). If subjects in Cohort 2 MRD progress prior to close of study, blood will be drawn for ctDNA testing.","label":"Cohort 2 minimal residual disease negative (MRD )","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2028-04","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer","NSCLC, Stage III","Nsclc"],"enrollment":{"count":48,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Durvalumab","otherNames":["Imfinzi","MEDI-4736","MEDI4736"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Carboplat","Carbosol","Carboplatino","cis-diammine(cyclobutane-1,1-dicarboxylato)platinum"],"type":"DRUG"},{"name":"Pemetrexed","otherNames":["Alimta","MTA","LY231514","L-glutamic acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Praxel"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["platinum diamminodichloride","Abiplatin","Cismaplat","cis-platinum","Platinex","platinum, diaminedichloro-, cis- (8CI)"],"type":"DRUG"},{"name":"AVENIO ctDNA Surveillance Kit","otherNames":[],"type":"DEVICE"},{"name":"Tremelimumab","otherNames":["Imjudo","Tremelimumab-actl","Ticilimumab","CP-675","CP-675,206"],"type":"DRUG"}],"last_update":"2026-09-30","lead_sponsor":"Stanford University","official_title":"ADAPT-C: Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Change in ctDNA Level Following Chemotherapy","timeFrame":"12 weeks"}],"references":[],"start_date":{"date":"2021-08-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC","url":"https://clinicaltrials.gov/study/NCT04585490"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/adapt-c-nct04585490"}